Geode Capital Management LLC raised its position in Chimerix, Inc. (NASDAQ:CMRX) by 11.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 341,238 shares of the biopharmaceutical company’s stock after buying an additional 35,752 shares during the period. Geode Capital Management LLC owned about 0.73% of Chimerix worth $2,177,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Teza Capital Management LLC acquired a new position in shares of Chimerix during the first quarter worth about $135,000. American International Group Inc. raised its position in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,733 shares during the period. Trexquant Investment LP acquired a new position in shares of Chimerix during the first quarter worth about $226,000. Nationwide Fund Advisors raised its position in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares during the period. Institutional investors own 67.53% of the company’s stock.

Shares of Chimerix, Inc. (NASDAQ:CMRX) traded down 0.23% during mid-day trading on Monday, hitting $4.37. The stock had a trading volume of 34,540 shares. The stock’s market cap is $205.59 million. Chimerix, Inc. has a 12-month low of $3.66 and a 12-month high of $6.64. The firm’s 50-day moving average price is $4.84 and its 200 day moving average price is $5.37.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.05. The business had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. Equities analysts forecast that Chimerix, Inc. will post ($1.63) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Geode Capital Management LLC Has $2.18 Million Stake in Chimerix, Inc. (CMRX)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/geode-capital-management-llc-has-2-18-million-stake-in-chimerix-inc-cmrx/1528174.html.

A number of brokerages have issued reports on CMRX. ValuEngine lowered Chimerix from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 9th. Finally, FBR & Co restated a “hold” rating and issued a $7.00 price objective on shares of Chimerix in a report on Monday, May 1st.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.